<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00171093</url>
  </required_header>
  <id_info>
    <org_study_id>CVAS489A2316</org_study_id>
    <nct_id>NCT00171093</nct_id>
  </id_info>
  <brief_title>A 10-12 Week Study to Evaluate the Safety and Efficacy of 320 mg Valsartan and 80 mg Simvastatin in Combination and as Monotherapies in Treating Hypertension and Hypercholesterolemia</brief_title>
  <official_title>A 10-12 Week Multicenter, Double-blind Study to Evaluate the Efficacy and Safety of the Combination of Valsartan (320 mg) and Simvastatin (80 mg) Compared to Valsartan (320 mg) and Simvastatin (80 mg) Monotherapies in Essential Hypertension and Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This 10-12 week study will provide data on the safety and efficacy of using 320 valsartan and
      80 mg simvastatin together compared to using either one alone in lowering blood pressure and
      LDL cholesterol. After discontinuing current drug therapies for hypertension and
      hypercholesterolemia, patients will be given 320mg valsartan+80mg simvastatin, 320mg
      valsartan+placebo, or 80mg simvastatin+placebo..
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <primary_completion_date type="Actual">January 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in average ambulatory systolic blood pressure over 24 hours</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in serum low density lipoprotein cholesterol (LDL-C )</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events and serious adverse events at each study visit for 42 days</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in average ambulatory systolic blood pressure over 24 hours between two different treatment therapies</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 24 hour ambulatory blood pressure in the daytime compared to nighttime</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 24 hour ambulatory blood pressure 21-24 hours after last dose of study medication</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total cholesterol, triglycerides, and high densitiy lipoprotein cholesterol (HDL-C) from baseline after 42 days</measure>
  </secondary_outcome>
  <enrollment>369</enrollment>
  <condition>HYPERTENSION</condition>
  <condition>HYPERCHOLESTEROLEMIA</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>valsartan + simvastatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ESSENTIAL HYPERTENSION

          -  ELEVATED LDL-C CHOLESTEROL

          -  USING STABLE DOSE OF HMG CoA REDUCTASE INHIBITOR (STATIN) FOR 3+ MONTHS

        Exclusion Criteria:

          -  SEVERE HYPERTENSION

          -  EVIDENCE OF HISTORY OR CURRENT HEART DISEASE

          -  HISTORY OF STROKE OR MYOCARDIAL INFARCTION

          -  DISLIPIDEMIA OR HYPERTENSION DUE TO SECONDARY CAUSES

          -  UNCONTROLLED DIABETES OR INSULIN

        Other protocol-defined exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Pharmaceuticals</name>
      <address>
        <city>E. Hanover</city>
        <state>New Jersey</state>
        <zip>07936</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=2410</url>
    <description>Results for CVAS489A2316 from the Novartis Clinical Trials website</description>
  </link>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2005</study_first_submitted>
  <study_first_submitted_qc>September 10, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>February 20, 2017</last_update_submitted>
  <last_update_submitted_qc>February 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <keyword>HYPERTENSION</keyword>
  <keyword>HYPERCHOLESTEROLEMIA</keyword>
  <keyword>BLOOD PRESSURE</keyword>
  <keyword>CHOLESTEROL</keyword>
  <keyword>VALSARTAN</keyword>
  <keyword>SIMVASTATIN</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Valsartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

